Evidence map›Paper›PMID 40103940›Full record

ReviewDigital biomarkers

Interpretation of Change in Novel Digital Measures: A Statistical Review and Tutorial.

Andrew Trigg, Bohdana Ratitch, Frank Kruesmann, Madhurima Majumder, Andrejus Parfionovas, Ulrike Krahn

Abstract readReview
In one paragraph

Review in Digital biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew TriggMedical Affairs Statistics, Bayer plc, Reading, Berkshire, UK.
Bohdana RatitchStatistics and Data Insights, Bayer Inc., Mississauga, ON, Canada.
Frank KruesmannStatistics and Data Insights, Bayer AG, Wuppertal, Germany.
Madhurima MajumderStatistics and Data Insights, Bayer US LLC, Whippany, NJ, USA.
Andrejus ParfionovasStatistics and Data Insights, Bayer US LLC, Whippany, NJ, USA.
Ulrike KrahnStatistics and Data Insights, Bayer AG, Wuppertal, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Novel clinical measures assessed by a digital health technology tool require thresholds to interpret change over time, such as the minimal clinically important difference. Establishing such thresholds is a key component of clinical validation, facilitating understanding of relevant treatment effects. Summary: Many of the approaches to derive interpretative thresholds for patient-reported outcomes can be applied to digital clinical measures. We present theoretical background to the use of interpretative thresholds, including the distinction between thresholds based on perceived importance versus measurement error, and thresholds for group- versus individual-level interpretations. We then review methods to estimate such thresholds, including anchor-based approaches. We illustrate the methods using data on cough frequency counts as measured by a wearable device in a clinical trial. Key Messages: This paper provides an overview of statistical methodologies to estimate thresholds for the interpretation of change.

Indexed as

Clinical validationDigital health technologyInterpretationMIDMinimal clinically important difference

Identifiers

PMID40103940
PMCPMC11919315

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.